Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirum Pharmaceuticals reports robust Q4 performance and growth strategies

Mirum Pharmaceuticals showcased strong financial performance and strategic growth initiatives in their Q4 2022 earnings call, driven by significant sales growth and positive study outcomes.
While the company faces challenges in maintaining market position and regulatory milestones, opportunities lie in upcoming milestones, product expansion, and market penetration strategies.
Overall, Mirum Pharmaceuticals' performance reflects a promising outlook for continued growth and innovation in the pharmaceutical sector, supported by a solid financial foundation and product pipeline.

Mirum Pharmaceuticals reports strong Q1 revenue and strategic growth plans

Mirum Pharmaceuticals' Q1 2023 earnings call showcased strong revenue performance, strategic initiatives, and promising pipeline milestones. The company's focus on LIVMARLI and expansion efforts position it well for future growth, despite facing regulatory and commercial challenges.

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use

The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company said on Wednesday.

US FDA approves expanded use of Mirum's liver disease drug

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum's LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.

Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals delivered solid Q4 results last week, with projected sales growth of around 70% for fiscal year 2024. The company's primary growth driver is Livmarli, an oral solution approved for the treatment of cholestatic pruritus for Alagille syndrome patients. MIRM has other promising compounds in its pipeline, including Volixibat, and is projected to become profitable in FY2025.

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024.

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging.

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #leadership--Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer.

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates.

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negative implications for Livmarli in other indications. Livmarli's strong start in ALGS and an incremental opportunity in PFIC put it in a good position for continued growth despite the increasing presence of Ipsen's Bylvay.

Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia.

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents New Data at The Liver Meeting®.

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head, R&D Eric Bjerkholt - CFO Conference Call Participants Josh Schimmer - Cantor Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners David Lebowitz - Citigroup Brian Skorney - Robert W. Baird & Co. Ed Arce - H.C.

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference.

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update.

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present New Data at The Liver Meeting®.

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

CECO Environmental Corp

Gatos Silver

Helios Technologies Inc

Ivanhoe Electric Inc / US

Kodiak Gas Services Inc

Obsidian Energy Ltd

While enterprises with diminutive market capitalizations tend to be high-risk, high-reward ventures, you can shift the odds in your favor with small-cap stocks with buy ratings. Thanks to the nod from Wall Street experts, you can feel a little bit more comfortable with the speculative step that you're taking.

News for Mirum Pharmaceuticals Inc Stock (MIRM)